» Articles » PMID: 38288698

Clinical and Preclinical Methods of Heat-Stabilization of Human Vaccines

Overview
Journal Mol Pharm
Specialty Pharmacology
Date 2024 Jan 30
PMID 38288698
Authors
Affiliations
Soon will be listed here.
Abstract

Vaccines have historically faced challenges regarding stability, especially in regions lacking a robust cold chain infrastructure. This review delves into established and emergent techniques to improve the thermostability of vaccines. We discuss the widely practiced lyophilization method, effectively transforming liquid vaccine formulations into a solid powdered state, enhancing storage and transportation ability. However, potential protein denaturation during lyophilization necessitates alternative stabilization methods. Cryoprotectants, namely, starch and sugar molecules, have shown promise in protecting vaccine antigens and adjuvants from denaturation and augmenting the stability of biologics during freeze-drying. Biomineralization, a less studied yet innovative approach, utilizes inorganic or organic-inorganic hybrids to encapsulate biological components of vaccines with a particular emphasis on metal-organic coordination polymers. Encapsulation in organic matrices to form particles or microneedles have also been studied in the context of vaccine thermostability, showing some ability to store outside the cold-chain. Unfortunately, few of these techniques have advanced to clinical trials that evaluate differences in storage conditions. Nonetheless, early trials suggest that alternative storage techniques are viable and emphasize the need for more comprehensive studies. This review underscores the pressing need for heat-stable vaccines, especially in light of the increasing global distribution challenges. Combining traditional methods with novel approaches holds promise for the future adaptability of vaccine distribution and use.

Citing Articles

The potential of nano- and microparticle-based influenza vaccines with enhanced shelf lives.

Ainslie K Nanomedicine (Lond). 2024; 19(26):2135-2138.

PMID: 39377099 PMC: 11486058. DOI: 10.1080/17435889.2024.2392484.

References
1.
Wibowo D, Jorritsma S, Gonzaga Z, Evert B, Chen S, Rehm B . Polymeric nanoparticle vaccines to combat emerging and pandemic threats. Biomaterials. 2020; 268:120597. PMC: 7834201. DOI: 10.1016/j.biomaterials.2020.120597. View

2.
Ju Y, Lee W, Pilkington E, Kelly H, Li S, Selva K . Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine. ACS Nano. 2022; 16(8):11769-11780. DOI: 10.1021/acsnano.2c04543. View

3.
Soto E, Specht C, Rus F, Lee C, Abraham A, Levitz S . An efficient (nano) silica - In glucan particles protein encapsulation approach for improved thermal stability. J Control Release. 2023; 357:175-184. DOI: 10.1016/j.jconrel.2023.03.027. View

4.
Asadi K, Gholami A . Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: A review. Int J Biol Macromol. 2021; 182:648-658. PMC: 8049750. DOI: 10.1016/j.ijbiomac.2021.04.005. View

5.
Chen D, Kapre S, Goel A, Suresh K, Beri S, Hickling J . Thermostable formulations of a hepatitis B vaccine and a meningitis A polysaccharide conjugate vaccine produced by a spray drying method. Vaccine. 2010; 28(31):5093-9. DOI: 10.1016/j.vaccine.2010.04.112. View